4722 related articles for article (PubMed ID: 6143562)
61. Clinical and molecular impact of inhibition of IMP dehydrogenase activity by tiazofurin.
Weber G; Yamaji Y; Olah E; Natsumeda Y; Jayaram HN; Lapis E; Zhen WN; Prajda N; Hoffman R; Tricot GJ
Adv Enzyme Regul; 1989; 28():335-56. PubMed ID: 2576178
[TBL] [Abstract][Full Text] [Related]
62. Modulation of nicotinamide adenine dinucleotide and poly(adenosine diphosphoribose) metabolism by the synthetic "C" nucleoside analogs, tiazofurin and selenazofurin. A new strategy for cancer chemotherapy.
Berger NA; Berger SJ; Catino DM; Petzold SJ; Robins RK
J Clin Invest; 1985 Feb; 75(2):702-9. PubMed ID: 3919063
[TBL] [Abstract][Full Text] [Related]
63. Effects of tiazofurin on protooncogene expression during HL-60 cell differentiation.
Kharbanda SM; Sherman ML; Spriggs DR; Kufe DW
Cancer Res; 1988 Nov; 48(21):5965-8. PubMed ID: 2901907
[TBL] [Abstract][Full Text] [Related]
64. In vivo antitumor activity of S 16020-2, a new olivacine derivative.
Guilbaud N; Kraus-Berthier L; Saint-Dizier D; Rouillon MH; Jan M; Burbridge M; Visalli M; Bisagni E; Pierré A; Atassi G
Cancer Chemother Pharmacol; 1996; 38(6):513-21. PubMed ID: 8823492
[TBL] [Abstract][Full Text] [Related]
65. Tiazofurin is phosphorylated by three enzymes from Chinese hamster ovary cells.
Saunders PP; Spindler CD; Tan MT; Alvarez E; Robins RK
Cancer Res; 1990 Sep; 50(17):5269-74. PubMed ID: 2143686
[TBL] [Abstract][Full Text] [Related]
66. Enzymic programs of rat bone marrow and the impact of acivicin and tiazofurin.
Prajda N; Natsumeda Y; Ikegami T; Reardon MA; Szondy S; Hashimoto Y; Emrani J; Weber G
Biochem Pharmacol; 1988 Mar; 37(5):875-80. PubMed ID: 3345200
[TBL] [Abstract][Full Text] [Related]
67. Eicar (5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide). A novel potent inhibitor of inosinate dehydrogenase activity and guanylate biosynthesis.
Balzarini J; Karlsson A; Wang L; Bohman C; Horská K; Votruba I; Fridland A; Van Aerschot A; Herdewijn P; De Clercq E
J Biol Chem; 1993 Nov; 268(33):24591-8. PubMed ID: 7901217
[TBL] [Abstract][Full Text] [Related]
68. Mechanism of resistance of variants of the Lewis lung carcinoma to N-(phosphonacetyl)-L-aspartic acid.
Kensler TW; Mutter G; Hankerson JG; Reck LJ; Harley C; Han N; Ardalan B; Cysyk RL; Johnson RK; Jayaram HN; Cooney DA
Cancer Res; 1981 Mar; 41(3):894-904. PubMed ID: 7459875
[TBL] [Abstract][Full Text] [Related]
69. Induction of HL60 cell differentiation by tiazofurin and its analogues: characterization and efficacy.
Goldstein BM; Leary JF; Farley BA; Marquez VE; Levy PC; Rowley PT
Blood; 1991 Aug; 78(3):593-8. PubMed ID: 1650262
[TBL] [Abstract][Full Text] [Related]
70. Molecular mechanisms in the antiproliferative action of taxol and tiazofurin.
Olah E; Csokay B; Prajda N; Kote-Jarai Z; Yeh YA; Weber G
Anticancer Res; 1996; 16(5A):2469-77. PubMed ID: 8917337
[TBL] [Abstract][Full Text] [Related]
71. Synergistic action of tiazofurin and retinoic acid on differentiation and colony formation of HL-60 leukemia cells.
Yamaji Y; Natsumeda Y; Yamada Y; Irino S; Weber G
Life Sci; 1990; 46(6):435-42. PubMed ID: 1968220
[TBL] [Abstract][Full Text] [Related]
72. In vivo activity on murine tumors of a novel antitumor compound, N-beta-dimethylaminoethyl 9-carboxy-5-hydroxy-10-methoxybenzo[a]phenazine-6-carboxamide sodium salt (NC-190).
Nakaike S; Yamagishi T; Samata K; Nishida K; Inazuki K; Ichihara T; Migita Y; Otomo S; Aihara H; Tsukagoshi S
Cancer Chemother Pharmacol; 1989; 23(3):135-9. PubMed ID: 2924370
[TBL] [Abstract][Full Text] [Related]
73. Studies on the mechanism of action of benzamide riboside: a novel inhibitor of IMP dehydrogenase.
Gharehbaghi K; Grünberger W; Jayaram HN
Curr Med Chem; 2002 Apr; 9(7):743-8. PubMed ID: 11966437
[TBL] [Abstract][Full Text] [Related]
74. Metabolism of tiazofurin by human erythrocytes and mononuclear blood cells in vitro.
Roberts JD; Tong WP; Hartshorn JN; Hacker MP
Cancer Lett; 1986 Aug; 32(2):193-7. PubMed ID: 3756845
[TBL] [Abstract][Full Text] [Related]
75. Alterations in nucleoside monophosphate concentrations in 3LL tumours after combined treatment with tiazofurin and 5-hexyl-2'-deoxyuridine.
Pogany G; Raso E; Peterszegi G; Keresztfalvi M; Lapis K; Jeney A
Anticancer Res; 1992; 12(1):281-4. PubMed ID: 1314534
[TBL] [Abstract][Full Text] [Related]
76. Activity and metabolism of 2-beta-D-ribofuranosylthiazole-4-carboxamide in human lymphoid tumor cells in culture.
Earle MF; Glazer RI
Cancer Res; 1983 Jan; 43(1):133-7. PubMed ID: 6182988
[TBL] [Abstract][Full Text] [Related]
77. Phase I study of tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide, NSC 286193).
Maroun JA; Stewart DJ
Invest New Drugs; 1990; 8 Suppl 1():S33-9. PubMed ID: 2380015
[TBL] [Abstract][Full Text] [Related]
78. Tiazofurin effects on IMP-dehydrogenase activity and expression in the leukemia cells of patients with CML blast crisis.
Wright DG; Boosalis MS; Waraska K; Oshry LJ; Weintraub LR; Vosburgh E
Anticancer Res; 1996; 16(6A):3349-51. PubMed ID: 9042310
[TBL] [Abstract][Full Text] [Related]
79. Regulation of purine and pyrimidine metabolism by insulin and by resistance to tiazofurin.
Weber G; Lui MS; Jayaram HN; Pillwein K; Natsumeda Y; Faderan MA; Reardon MA
Adv Enzyme Regul; 1985; 23():81-99. PubMed ID: 3907307
[TBL] [Abstract][Full Text] [Related]
80. Effectiveness of tiazofurin (NSC 286193) in treating disseminated tumor cells and micrometastases in mice.
Lapis K; Pápay J; Paku S
Oncology; 1990; 47(4):359-64. PubMed ID: 2367062
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
